PerpEquities

Equity · Healthcare

SELLAS Life Sciences Group, Inc. (SLS) perpetual futures

SLS perpetual futures on 1 crypto exchange – live perp price vs the stock, funding rate, open interest and where to trade SLSUSDT.

SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company developing novel cancer therapeutics, led by the peptide immunotherapy galinpepimut-S (GPS) and the CDK9 inhibitor SLS009 (tambiciclib).

$14.69+2.6%NASDAQ closed
Open in terminal

Price chart

 

Use the left and right arrow keys to inspect points on the chart.

venue perp mark · MEXC (SLS/USDT)
Auto: highest-volume live perp venueOpen in TradingView

Trading data

Perpetual market activity

1/1 live markets
Venues
1
Live markets
1/1
24h volume
$162.2K
Open interest
$234.2K
Best liquidity
$0
MEXC
Tightest spread
+524.0 bps
MEXC
Highest volume
$162.2K
MEXC
Settlement mix
USDT · 1/1
Perp/spot vol.
0.00x
Spot volume $225.8M
OI / float
+0.01%
Float $3B
Spot performance
1D-8.08%
5D+76.49%
1M+20.35%
6M+75.58%
YTD+262.33%
1Y+781.29%

Venue matrix

1 markets

Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.

Trade
MEXCTradeSLS/USDTTrading$14.69+14.1% APR
+0.013% every 8h
+524.0 bps$0$162.2K$234.2KUSDT20x

Tradability

Execution quality

Entry cost and depth per venue at $1k–$100k

No sufficient depth · 0 of 1 venues absorb $10k

No fresh book data: MEXC

Taker execution estimate incl. approx. fees - maker fills are not guaranteed.

Best venues for this underlying

Best liquidity

SLS

Tightest spread

SLS

Highest volume

SLS

Funding history

Stored venue snapshots by market

Company financials

Financials at a glance

Last report Q3 '26 · filed 2026-11-12 · next report 2027-03-25 · Updated 2h ago
All financials →

Valuation & key figures

Market cap
$2.78B
Updated 2h ago
Revenue
$0
Trailing 12 months
Revenue growth
–
FY2026 consensus
Profit margin
–
Net income / revenue, TTM
P/E
No P/E
Loss in the last twelve months
P/S
–
Price / sales, TTM
Peer P/E
45.1×
Similar listed perps
EV / EBITDA
-74.1×
TTM
Free cash flow
-$27.3M
Trailing 12 months
Net income
-$35.8M
Trailing 12 months
Revenue estimate
$36.1M
FY2026 consensus
Earnings
2027-03-25
Revenue est. $36.1M · Updated 2h ago
Dividend
–
No dividend
Revenue (TTM)$0– vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)–– vs a year agoOperating income -$39.4M
Net income (TTM)-$35.8M-37.8% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)-$27.3M+10.9% vs a year agoCapex $0
Diluted EPS (TTM)-$0.20+31.5% vs a year agoSum of the last 4 quarters
Net cash$134M+206.0% vs a year agoCash + short-term investments - debt
  • Last report (2026-11-12): revenue n/a, EPS in lineRevenue – vs – expected (–); EPS -$0.05 vs -$0.05 (0.0%).
  • Diluted share count up 86.8% in a year202M diluted shares in Q3 '26, 108M a year earlier.
  • Net cash $134MCash + short-term investments $135M, debt incl. leases $599K; a year ago net cash $43.8M.

Revenue, operating income and growth

quarterly
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates · all 135 lines SELLAS Life Sciences Group, Inc. reported to the SEC

Next catalyst

Catalysts

Earnings
2027-03-25
Revenue est. $36.1M · Updated 2h ago

No unusual perp activity right now.

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 2026-0.20$36.1M+13%1
FY 2027-0.25$54.7M+51%2
FY 2028-0.02$78.9M+44%2
FY 20290.36$185.8M+136%1
FY 20302.68$789.1M+325%1
Q3 2026-0.05$0-1
Source: FMP · Consensus

Company events

6
2027-03-25EarningsActual - / Estimate -0.05-
2026-11-12EarningsActual -0.05 / Estimate -0.05In line
2026-08-11EarningsActual -0.05 / Estimate -0.045Miss
2026-05-12EarningsActual -0.05 / Estimate -0.06Beat
2026-03-19EarningsActual -0.05 / Estimate -0.0633Beat
2025-11-12EarningsActual -0.06 / Estimate -0.0633Beat

Peer comparison

Similar listed perps

Company data

Company intelligence

Updated: Nov 22, 2026, 11:57 AM UTC

Company profile

Sector
Healthcare
Industry
Biotechnology
Chief executive
Angelos Stergiou
Employees
13
IPO date
Mar 12, 2008
Country
US
Exchange
NASDAQ
Website
Altman Z-scorei249.42
Piotroski scorei2/9
Overall ratingiC
Owner earningsi-$5.94M-$0.03 per share
ESG risk ratingiB-Industry rank: 723/728

Rating factors

Return on equityi
1/5
Return on assetsi
1/5
Debt to equityi
4/5
Price to earningsi
1/5
Price to booki
1/5
Market cap history
$2.77B+2.0%Aug 2026 – Nov 2026
$1.51B$2.14B$2.77BLow: $1.51B · 2026-11-16Latest: $2.77B · 2026-11-20Aug 2026Sep 2026Oct 2026Nov 2026
Latest: $2.77B · 2026-11-20High: $2.77B · 2026-11-20Low: $1.51B · 2026-11-16
Largest fund holders
FundWeightShares held
XBI0.44%5.8M
IWM0.05%5.2M
VTS.AX0%5.1M
NJM0.04%4M
VXF0.02%2.3M
IWO0.1%1.9M
NLO0.08%1.4M
FSSNX0.08%1.4M
VTWO0.06%1.2M
SCHA0.04%1.1M
IWC0.39%615.2K
VHT0.02%603.2K

Analyst track record

How the analysts covering SLS have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings1136
Analysts34
Buy / hold / sell11 / 0 / 036 / 0 / 0
Upgrades / downgrades / initiations0 / 0 / 00 / 0 / 0
Price targets hit / missed7 / 4 (64%)32 / 4 (89%)
Avg. return after a rating (TipRanks)+59.2%+241.5%
Best / worst call+173.6% / -52.1%+378.8% / -52.1%

After buy calls on this stock: median 21-day move +7.5% vs S&P 500 +4.8% (n = 35)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Jason McCarthyMaxim Group50% hit rate on this stock · 22 targets measuredBuytarget $40.00Nov 17, 2026

Latest ratings

DateAnalystCallTarget
Nov 17, 2026Jason McCarthyMaxim GroupNov 17, 2026BuyMaintained$40.00↗
Nov 13, 2026Jason McCarthyMaxim GroupNov 13, 2026BuyMaintained$30.00↗
Jul 6, 2026James MolloyAlliance Global PartnersJul 6, 2026BuyReiterated$25.00↗
Jul 6, 2026Matthew VeneziaAlliance Global PartnersJul 6, 2026BuyReiterated$25.00↗
May 14, 2026Jason McCarthyMaxim GroupMay 14, 2026BuyReiterated$10.00↗
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$5.00$10.00$15.00$20.00$25.00$30.00Dec 25 · Buy 2 · Hold 0 · Sell 0Dec 25Jan 26 · Buy 2 · Hold 0 · Sell 0Feb 26 · Buy 2 · Hold 0 · Sell 0Feb 26Mar 26 · Buy 2 · Hold 0 · Sell 0Apr 26 · Buy 2 · Hold 0 · Sell 0Apr 26May 26 · Buy 2 · Hold 0 · Sell 0Jun 26 · Buy 2 · Hold 0 · Sell 0Jun 26Jul 26 · Buy 3 · Hold 0 · Sell 0Aug 26 · Buy 3 · Hold 0 · Sell 0Aug 26Sep 26 · Buy 3 · Hold 0 · Sell 0Oct 26 · Buy 3 · Hold 0 · Sell 0Oct 26Nov 26 · Buy 3 · Hold 0 · Sell 0Dec 25 · avg. target $7.25Jan 26 · avg. target $7.25Feb 26 · avg. target $7.25Mar 26 · avg. target $10.00Apr 26 · avg. target $10.00May 26 · avg. target $10.00Jun 26 · avg. target $10.00Jul 26 · avg. target $20.00Aug 26 · avg. target $20.00Sep 26 · avg. target $20.00Oct 26 · avg. target $20.00Nov 26 · avg. target $30.00Dec 25 · month-end close $3.77Jan 26 · month-end close $3.77Feb 26 · month-end close $4.93Mar 26 · month-end close $4.23Apr 26 · month-end close $4.95May 26 · month-end close $9.31Jun 26 · month-end close $14.76Jul 26 · month-end close $10.01Aug 26 · month-end close $13.34Sep 26 · month-end close $12.31Oct 26 · month-end close $9.68Nov 26 · month-end close $13.66

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data · computed Nov 18, 2026 · 11 ratings

Frequently asked questions

Where can I trade SLS perpetual futures?

SELLAS Life Sciences Group, Inc. (SLS) perpetual futures trade on one crypto venue: MEXC. PerpEquities shows its live price, funding rate, open interest and liquidity.

Can I trade SLS around the clock?

Yes. Unlike the underlying stock, SLS perpetuals trade 24/7 — including weekends and outside regular market hours.

What is the funding rate on SLS perpetuals?

Right now the SLS perp funding rate is +14.1% annualized (one venue). A positive rate means longs pay shorts. PerpEquities shows the live rate and its history.

How does the SLS perp price compare to the SELLAS Life Sciences Group, Inc. stock?

The venue-median SLS perp mark is $14.7 versus a reference stock price of $14.7, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.

What is a SLS perpetual future?

A SLS perpetual is a derivative that tracks the price of SELLAS Life Sciences Group, Inc. with no expiry date. It lets you take long or short exposure to SELLAS Life Sciences Group, Inc. on crypto venues, around the clock.

What is SLSUSDT perpetual?

SLSUSDT is the symbol most crypto exchanges use for the SELLAS Life Sciences Group, Inc. perpetual settled in USDT (Tether). It tracks the SLS share price through an index, trades 24/7 with leverage and never expires.

Embed this asset

SLS perpetuals · perpequities.comSLS perpetuals · perpequities.com
<a href="https://perpequities.com/stocks/sls-perp"><img src="https://perpequities.com/badge/sls-perp.svg" width="240" height="64" alt="SLS perpetuals · perpequities.com" loading="lazy"></a>

Next step

Stay on top of SLS perps

Signals with a track record

Analysts who hit 70%+ of their targets on the perps we track, congress buys over $500k, 13F positions over $5M, funding spreads that have paid for days. Every post shows the evidence. Free, no sign-up.

Join on Telegram

Weekly digest by email

The listings, funding and moves that matter for SLS — one email every Sunday.

Watchlist and alerts

Price and funding alerts for SLS, via push or Telegram.

Set an alert

Follow the live feed

Daily movers, new listings and funding extremes as they happen.

Follow on X